MedTech Advisory Board Member

About Pumpinheart Heart failure treatment has advanced dramatically, yet for the millions of patients with Advanced Stage HFpEF (Heart Failure with Preserved Ejection Fraction), effective therapies that extend life remain unavailable. Pumpinheart fixes this. Pumpinheart is developing the world’s first transcatheter, implantable ECG-gated diastolic heart pump, designed specifically for Advanced Stage HFpEF. Originating from research at the Royal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences, Pumpinheart represents a new category of minimally invasive mechanical circulatory support addressing the single greatest unmet need in cardiovascular disease. Advanced Stage HFpEF affects approximately 50% of all advanced heart failure patients, many of whom suffer debilitating symptoms with limited treatment options. Existing therapies fail to effectively address elevated left atrial pressure during diastole, the core physiological driver of HFpEF. Pumpinheart’s technology delivers targeted diastolic unloading designed to: Reduce left atrial pressure Improve cardiac filling Allow patients breathless at rest to breathe freely again Improve exercise tolerance and quality of life Extend life expectancy by many years This breakthrough innovation is delivered via a minimally invasive outpatient cath-lab procedure, typically requiring only one overnight stay. Pumpinheart’s foundation is built on deep cardiovascular research, advanced simulation, and early feasibility studies, and the company is now preparing for expanded clinical validation and strategic partnerships across the U.S. and Europe. The Opportunity Pumpinheart is expanding its high-impact MedTech Advisory Board, bringing together leaders across medical devices, digital health, healthcare systems, commercialization, and cardiovascular innovation. We are seeking experienced health tech executives, operators, and strategists to help guide the development, validation, and adoption of one of the first transcatheter devices purpose-built for HFpEF. As a MedTech Advisory Board Member, you will play a critical role in positioning Pumpinheart for clinical and commercial success ensuring that our technology, workflows, and market strategy align with the realities of modern healthcare systems, medtech adoption, and enterprise deployment. Advisors Will Help Shape Integration of Pumpinheart’s device into cardiology, interventional cardiology, HF clinics, and cath-lab workflows Optimization of pathways for clinical trials, regulatory approval, and early commercial adoption Scalable deployment models for hospitals, health systems, and advanced heart-failure programs Go-to-market strategy, KOL engagement, and early adoption roadmaps Real-world evidence generation and long-term clinical validation Strategic connections across cardiovascular centers, health systems, and medtech ecosystems Advisors will receive early visibility into Pumpinheart’s current fundraising round, with the opportunity to participate alongside clinicians, medtech leaders, and institutional supporters. Key Responsibilities Clinical Workflow, Integration & Regulatory Pathways Advise on integration of Pumpinheart into HF, cardiology, and cath-lab workflows Provide strategic input on clinical trial design, regulatory pathways, and endpoint selection Share insights on procedural workflow, device positioning, and clinical data requirements Go-to-Market Strategy & Strategic Connections Introduce Pumpinheart to health systems, heart-failure programs, interventional cardiology leaders, and medtech partners Support expansion across priority markets in the U.S. and E.U. Advise on health-system engagement, payer strategy, and market rollout sequencing Product & Market Insight Offer feedback on device usability, clinician experience, and procedural efficiency Advise on patient selection, outcomes measurement, and adoption barriers Provide insight into pricing strategy, reimbursement pathways, and commercial differentiation Clinical or Technical Expertise Clinical, engineering, or health-system leadership background in cardiology, devices, or health tech is valued but not required. Ideal Advisor Profiles We are especially interested in individuals with at least 3 of the following: 10+ years in health tech, medtech, cardiology innovation, or health-system leadership Experience scaling medical devices, digital health platforms, or regulated technologies Expertise in reimbursement strategy, payer engagement, or value-based care pathways Leadership experience within hospital systems, medtech companies, or enterprise healthcare organizations Strong networks across health systems, cardiovascular innovation, or medtech commercialization Interest in minimally invasive cardiac technologies and breakthrough devices Passion for improving HFpEF outcomes and reducing the global burden of heart failure Founding Team Donald Hickey - Co-Founder & CEO Serial entrepreneur with a track record of building and scaling technology companies. Leads corporate strategy, partnerships, commercialization planning, and fundraising. Dr. Aamir Hameed - Co-Founder & Chief Medical Officer Clinician-scientist and RCSI academic with a background in cardiothoracic surgery. Leads clinical strategy, risk-benefit analysis, and first-in-human planning. Dr. Andrew Malone - Co-Founder & Chief Scientific Officer Medical physicist specializing in cardiovascular device development and simulation engineering. Oversees prototyping, preclinical testing, and core technology development. Jonathan Bouchier-Hayes - Non-Executive Director CEO of Endowave with extensive experience taking minimally invasive devices from concept to market. Advises on commercialization and regulatory readiness. Dr. Faisal H. Cheema - Non-Executive Director CEO of ClinRé CRO and Associate Professor at the University of Houston. Renowned physician-scientist entrepreneur supporting clinical strategy, trials, and KOL engagement. Compensation & Engagement Equity-based advisory compensation 1–2 hours per month (fully remote) Access to internal strategy documents, clinical roadmap discussions, and investor updates Option to participate in current or future Pumpinheart funding rounds Equal Opportunity Commitment Pumpinheart is committed to building a diverse, mission-aligned advisory board. We welcome professionals from all backgrounds and perspectives and are proud to be an equal opportunity organization.

Created: 2026-03-04